Under the microscope with Dr Jeffrey A. Borgia, Rush University Medical Center
Posted: 20 September 2016 | Dr Jeffrey Borgia (Associate Professor: Rush University Medical Center) | No comments yet
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer…
Industry trends in biomarker developments
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer.
Currently, Dr Jeffrey A. Borgia, an Associate Professor at Rush University Medical Center in Chicago, IL is refining a simple and cost-effective blood test that will serve as a companion test for lung cancer screening. His lab has developed a risk-stratifying tool that will help guide treatment for patients with suspected lung cancer. His test is based on ‘multiple analyses’ and performed using the Luminex® platform. Its main strength is its high negative predictive value, which is an attractive means to help reduce the large numbers of false positives resulting from low-dose computed tomography-based lung cancer screening protocols. His group is trying to create more effective screening protocols which will reduce the mortality statistics in the near future…
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!